Gene-set analysis based on the pharmacological profiles of drugs to identify repurposing opportunities in schizophrenia.
- Authors
- de Jong, Simone; Vidler, Lewis R; Mokrab, Younes; Collier, David A; Breen, Gerome
- Year
- 2016
- Journal
- Journal of psychopharmacology (Oxford, England)
- PMID
- 27302942
- DOI
- 10.1177/0269881116653109
Genome-wide association studies (GWAS) have identified thousands of novel genetic associations for complex genetic disorders, leading to the identification of potential pharmacological targets for novel drug development. In schizophrenia, 108 conservatively defined loci that meet genome-wide significance have been identified and hundreds of additional sub-threshold associations harbour information on the genetic aetiology of the disorder. In the present study, we used gene-set analysis based on the known binding targets of chemical compounds to identify the 'drug pathways' most strongly associated with schizophrenia-associated genes, with the aim of identifying potential drug repositioning opportunities and clues for novel treatment paradigms, especially in multi-target drug development. We compiled 9389 gene sets (2496 with unique gene content) and interrogated gene-based p-values from the PGC2-SCZ analysis. Although no single drug exceeded experiment wide significance (corrected p<0.05), highly ranked gene-sets reaching suggestive significance including the dopamine receptor antagonists metoclopramide and trifluoperazine and the tyrosine kinase inhibitor neratinib. This is a proof of principle analysis showing the potential utility of GWAS data of schizophrenia for the direct identification of candidate drugs and molecules that show polypharmacy.
No figures extracted from this document.
No chunks — full text not yet ingested.
No entities extracted from this document yet.
No uploaded files.
No citations found.
In this knowledge base
External
| Title | Authors | Journal | Year | Link |
|---|---|---|---|---|
| Linking Genome-Wide Association Studies to Pharmacological Treatments for Psychiatric Disorders. | Arnatkeviciute A et al. | — | 2025 | → |
| Network-based drug repurposing for psychiatric disorders using single-cell genomics. | Gupta C et al. | — | 2025 | → |
| Psychiatric genome-wide association study enrichment shows promise for future psychopharmaceutical discoveries. | Hatoum AS et al. | — | 2025 | → |
| A study of long-term GABA and high-energy phosphate alterations in the primary motor cortex using anodal tDCS and <sup>1</sup>H/<sup>31</sup>P MR spectroscopy. | Patel HJ et al. | — | 2024 | → |
| 15 years of GWAS discovery: Realizing the promise. | Abdellaoui A et al. | — | 2023 | → |
| Advancing the use of genome-wide association studies for drug repurposing. | Reay WR et al. | — | 2021 | → |
| Signature-based approaches for informed drug repurposing: targeting CNS disorders. | Shukla R et al. | — | 2021 | → |
| Integrative Omics for Informed Drug Repurposing: Targeting CNS Disorders | Shukla R et al. | — | 2020 | — |
| Targeted lipid nanoparticles for RNA therapeutics and immunomodulation in leukocytes. | Veiga N et al. | — | 2020 | → |
| The influence of common polygenic risk and gene sets on social skills group training response in autism spectrum disorder. | Li D et al. | — | 2020 | → |
| Turning genome-wide association study findings into opportunities for drug repositioning. | Lau A et al. | — | 2020 | → |
| Translating GWAS findings into therapies for depression and anxiety disorders: gene-set analyses reveal enrichment of psychiatric drug classes and implications for drug repositioning. | So HC et al. | — | 2019 | → |
| Using genetic drug-target networks to develop new drug hypotheses for major depressive disorder. | Gaspar HA et al. | — | 2019 | → |
| Post-GWAS in Psychiatric Genetics: A Developmental Perspective on the "Other" Next Steps. | Dick DM et al. | — | 2018 | → |
| 10 Years of GWAS Discovery: Biology, Function, and Translation. | Visscher PM et al. | — | 2017 | → |
| Analysis of genome-wide association data highlights candidates for drug repositioning in psychiatry. | So HC et al. | — | 2017 | → |
| Drug enrichment and discovery from schizophrenia genome-wide association results: an analysis and visualisation approach. | Gaspar HA et al. | — | 2017 | → |
| Translating genome-wide association findings into new therapeutics for psychiatry. | Breen G et al. | — | 2016 | → |